Alterity Therapeutics CEO to present on October 12

Alterity says it is preparing to initiate a Phase 3 pivotal trial in MSA, which it describes as a rare and rapidly progressive disease.

Rhea-AI Filing Summary

Alterity Therapeutics Limited (ATHE) announced that Chief Executive Officer David Stamler, M.D., will present at the Canaccord Genuity Drug and Device Conference on October 12, 2026, at 3:50 p.m. AEST and host roundtable discussions with investors.

The clinical-stage biotechnology company focuses on disease-modifying therapies for multiple system atrophy (MSA) and related Parkinsonian disorders. Alterity identifies ATH434 as its lead asset and says it demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in participants with MSA. The company also reports positive data from an open-label Phase 2 trial in participants with advanced MSA.

Key Figures

Presentation date: October 12, 2026 Presentation time: 3:50 p.m. AEST Planned trial phase: Phase 3 +2 more

5 metrics

Presentation date October 12, 2026 Canaccord Genuity Drug and Device Conference

Presentation time 3:50 p.m. AEST October 12, 2026

Planned trial phase Phase 3 Alterity is preparing to initiate a pivotal trial in MSA

Clinical trial phase Phase 2 Randomized, double-blind, placebo-controlled trial in participants with MSA

Clinical trial phase Phase 2 Open-label trial in participants with advanced MSA

Key Terms

Multiple System Atrophy (MSA), randomized, double-blind, placebo-controlled, open label, pivotal trial

4 terms

Multiple System Atrophy (MSA) medical

"therapies in Multiple System Atrophy (MSA)"

A progressive neurological disorder in which brain cells that control movement, balance and automatic body functions (like blood pressure, bladder control and digestion) gradually fail, causing symptoms such as poor coordination, stiffness, fainting and urinary problems. Investors care because the condition drives demand for diagnostic tests, therapies and long-term care solutions; successful clinical trials, regulatory approvals or setbacks can materially affect the valuation and revenue prospects of companies developing treatments, devices or related services.

randomized, double-blind, placebo-controlled medical

"randomized, double-blind, placebo-controlled Phase 2 clinical trial"

A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

open label medical

"open label Phase 2 clinical trial"

Open label is a clinical trial design in which both the participants and the researchers know which treatment or intervention is being given. For investors, this matters because knowledge of the treatment can influence reported effects and side effects—like how seeing a product label can change a shopper’s opinion—so open-label results are useful for safety and real-world experience but are generally viewed as less rigorous evidence of effectiveness than blinded studies.

pivotal trial medical

"Phase 3 pivotal trial in MSA"

A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Alterity Therapeutics (ATHE) presenting at the Canaccord Genuity Drug and Device Conference?

Chief Executive Officer David Stamler, M.D., is scheduled to present on October 12, 2026, at 3:50 p.m. AEST, and will host roundtable discussions with investors.

What is Alterity Therapeutics (ATHE) preparing for in MSA?

Alterity says it is preparing to initiate a Phase 3 pivotal trial in MSA, which it describes as a rare and rapidly progressive disease.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/09/2026 - 06:04 AM Accepted by SEC EDGAR 10/09/2026 - 06:00 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (File No. 333-274816)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1 Alterity to Present at Canaccord Drug and Device Conference

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alterity Therapeutics Limited
	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

Date: October 9, 2026

2

Exhibit 99.1

Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference 

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 9 October 2026:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia.

At the conference, Dr. Stamler will deliver a corporate presentation and will also host roundtable discussions with investors.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.

Authorization & Additional Information

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Contacts:

Investors

Elyse Shapiro

ir@alteritytx.com

Remy Bernarda

Investor Relations Advisory Solutions

ir@alteritytx.com

+1 (415) 203-6386

Media

Melissa Tempra

NWR Communications

melissa@nwrcommunications.com.au

Casey McDonald

Tiberend Strategic Advisors, Inc.

cmcdonald@tiberend.com

+1 (646) 577-8520

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 8.0 KB